{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:48Z","timestamp":1790007348111,"version":"4.0.1"},"publisher-location":"New York, NY","reference-count":110,"publisher":"Springer US","isbn-type":[{"value":"9781071650363","type":"print"},{"value":"9781071650370","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5037-0_17","type":"book-chapter","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:28:00Z","timestamp":1778452080000},"page":"241-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies"],"prefix":"10.1007","author":[{"given":"Anri","family":"Saitoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"12","key":"17_CR1","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.3390\/ijms22126321","volume":"22","author":"P Karagianni","year":"2021","unstructured":"Karagianni P, Giannouli S, Voulgarelis M (2021) From the (epi)genome to metabolism and vice versa; examples from hematologic malignancy. Int J Mol Sci 22(12):6321","journal-title":"Int J Mol Sci"},{"key":"17_CR2","volume-title":"StatPearls [Internet]","author":"MT Amjad","year":"2024","unstructured":"Amjad MT, Chidharla A, Kasi A (2024) Cancer chemotherapy. StatPearls [Internet]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564367\/. Date Accessed: 21 Nov 2024"},{"issue":"5","key":"17_CR3","first-page":"437","volume":"71","author":"K Wang","year":"2021","unstructured":"Wang K, Tepper JE (2021) Radiation therapy-associated toxicity: etiology, management, and prevention. CA Cancer J Clin 71(5):437\u2013454","journal-title":"CA Cancer J Clin"},{"key":"17_CR4","doi-asserted-by":"publisher","unstructured":"Alfarouk KO, Stock CM, Taylor S et al (2015) Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 15:71. https:\/\/doi.org\/10.1186\/s12935-015-0221-1","DOI":"10.1186\/s12935-015-0221-1"},{"issue":"1","key":"17_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T (2023) Molecular mechanisms of tumor resistance to radiotherapy. Mol Canc 22(1):96","journal-title":"Mol Canc"},{"issue":"1","key":"17_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6(1):201","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"17_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02287-3","volume":"20","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Li M (2022) Targeted therapies for cancer. BMC Med 20(1):90","journal-title":"BMC Med"},{"issue":"1","key":"17_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","volume":"14","author":"A Sochacka-\u0106wik\u0142a","year":"2021","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M, Regiec A (2021) FDA-approved drugs for hematological malignancies\u2014the last decade review. Cancers (Basel) 14(1):87. https:\/\/doi.org\/10.3390\/cancers14010087","journal-title":"Cancers (Basel)"},{"issue":"9","key":"17_CR9","doi-asserted-by":"publisher","first-page":"e14291","DOI":"10.15252\/emmm.202114291","volume":"13","author":"S Wang","year":"2021","unstructured":"Wang S, Chen K, Lei Q et al (2021) The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med 13(9):e14291","journal-title":"EMBO Mol Med"},{"key":"17_CR10","doi-asserted-by":"publisher","unstructured":"van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB (2019) Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol 10:548. https:\/\/doi.org\/10.3389\/fimmu.2019.00548","DOI":"10.3389\/fimmu.2019.00548"},{"key":"17_CR11","volume-title":"Immunobiology: the immune system in health and disease","author":"CA Janeway Jr","year":"2001","unstructured":"Janeway CA Jr, Travers P, Walport M, et al (2001) The structure of a typical antibody molecule. Immunobiology: the immune system in health and disease. 5th edn. Garland Science, New York, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27144\/","edition":"5th edn"},{"key":"17_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","volume":"201","author":"FV Suurs","year":"2019","unstructured":"Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA (2019) A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther 201:103\u2013119","journal-title":"Pharmacol Ther"},{"issue":"3","key":"17_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen Y, Park J et al (2019) Design and production of bispecific antibodies. Antibodies (Basel) 8(3):43","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"17_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell J, Lammers PE, Djuretic I et al (2019) Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther 106(4):781\u2013791","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"17_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","volume":"7","author":"M Lejeune","year":"2020","unstructured":"Lejeune M, K\u00f6se MC, Duray E et al (2020) Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol 7(11):762","journal-title":"Front Immunol"},{"issue":"6","key":"17_CR16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","volume":"8","author":"C Klein","year":"2016","unstructured":"Klein C, Schaefer W, Regula JT (2016) The use of CrossMAb technology for the generation of bi- and multispecific antibodies. Mabs 8(6):1010\u20131020","journal-title":"Mabs"},{"issue":"1","key":"17_CR17","doi-asserted-by":"publisher","first-page":"2018960","DOI":"10.1080\/19420862.2021.2018960","volume":"14","author":"D Yanakieva","year":"2022","unstructured":"Yanakieva D, Pekar L, Evers A et al (2022) Beyond bispecificity: controlled Fab arm exchange for the generation of antibodies with multiple specificities. Mabs 14(1):2018960","journal-title":"Mabs"},{"key":"17_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pep.2016.01.014","volume":"121","author":"S Paul","year":"2016","unstructured":"Paul S, Connor J, Nesspor T et al (2016) An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants. Protein Expr Purif 121:133\u2013140","journal-title":"Protein Expr Purif"},{"issue":"5","key":"17_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Er Saw P, Song E (2020) Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 17(5):451\u2013461","journal-title":"Cell Mol Immunol"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2019.04.004","volume":"81","author":"B Moshaver","year":"2019","unstructured":"Moshaver B, Wouters RF, Kelder A et al (2019) Relationship between CD34\/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. Leuk Res 81:27\u201334","journal-title":"Leuk Res"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"1020003","DOI":"10.3389\/fimmu.2022.1020003","volume":"13","author":"J Kang","year":"2022","unstructured":"Kang J, Sun T, Zhang Y (2022) Immunotherapeutic progress and application of bispecific antibody in cancer. Front Immunol 13:1020003","journal-title":"Front Immunol"},{"issue":"6","key":"17_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/life11060465","volume":"11","author":"C Allen","year":"2021","unstructured":"Allen C, Zeidan AM, Bewersdorf JP (2021) BiTEs, DARTS, BiKEs and TriKEs\u2014are antibody based therapies changing the future treatment of AML?. Life 11(6):465","journal-title":"Life"},{"issue":"8","key":"17_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14712598.2022.2072209","volume":"22","author":"RP Chen","year":"2022","unstructured":"Chen RP, Shinoda K, Rampuria P et al (2022) Bispecific antibodies for immune cell retargeting against cancer. Expert Opin Biol Ther 22(8):965\u2013982","journal-title":"Expert Opin Biol Ther"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fcell.2019.00370","volume":"7","author":"P Roda-Navarro","year":"2019","unstructured":"Roda-Navarro P, \u00c1lvarez-Vallina L (2019) Understanding the spatial topology of artificial immunological synapses assembled in T cell-redirecting strategies: a major issue in cancer immunotherapy. Front Cell Dev Biol 7:370","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"17_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1073\/pnas.96.1.185","volume":"96","author":"PA Bretscher","year":"1999","unstructured":"Bretscher PA (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 96(1):185\u2013190","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR26","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M (2022) Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 13:1035276","journal-title":"Front Immunol"},{"issue":"6332","key":"17_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T et al (2017) Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355(6332):1423\u20131427","journal-title":"Science"},{"issue":"7900","key":"17_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","volume":"603","author":"E Seung","year":"2022","unstructured":"Seung E, Xing Z, Wu L et al (2022) A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature 603(7900):328\u2013334","journal-title":"Nature"},{"issue":"15","key":"17_CR29","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1158\/1078-0432.CCR-21-2762","volume":"28","author":"JK Peper-Gabriel","year":"2022","unstructured":"Peper-Gabriel JK, Pavlidou M, Pattarini L et al (2022) The PD-L1\/4-1BB bispecific antibody-anticalin fusion protein PRS-344\/S095012 elicits strong T-cell stimulation in a tumor-localized manner. Clin Cancer Res 28(15):3387\u20133399","journal-title":"Clin Cancer Res"},{"issue":"7","key":"17_CR30","doi-asserted-by":"publisher","first-page":"e002428","DOI":"10.1136\/jitc-2021-002428","volume":"9","author":"S Jeong","year":"2021","unstructured":"Jeong S, Park E, Kim HD et al (2021) Novel anti-4-1BB\u00d7PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer 9(7):e002428. https:\/\/doi.org\/10.1136\/jitc-2021-002428","journal-title":"J Immunother Cancer"},{"issue":"19","key":"17_CR31","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","volume":"25","author":"MJ Hinner","year":"2019","unstructured":"Hinner MJ, Aiba RSB, Jaquin TJ et al (2019) Tumor-localized costimulatory T-cell engagement by the 4-1BB\/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res 25(19):5878\u20135889","journal-title":"Clin Cancer Res"},{"key":"17_CR32","doi-asserted-by":"crossref","unstructured":"Hutchings M, Dickinson MJ, Gritti G et al (2024) Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r\/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072. Blood 144(Supplement 1):990.","DOI":"10.1182\/blood-2024-200096"},{"key":"17_CR33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/CMAR.S351383","volume":"14","author":"A Karczmarczyk","year":"2022","unstructured":"Karczmarczyk A, Korpysz M, Bilska S et al (2022) Programmed cell death-1 and its ligands as targets for therapy of multiple myeloma patients. Cancer Manag Res 14:1267\u20131281","journal-title":"Cancer Manag Res"},{"issue":"12","key":"17_CR34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14728222.2022.2170781","volume":"26","author":"M Sadeghi","year":"2022","unstructured":"Sadeghi M, Khodakarami A, Ahmadi A et al (2022) The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert Opin Ther Targets 26(12):1057\u20131071","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"17_CR35","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2016.148965","volume":"102","author":"M Shapiro","year":"2017","unstructured":"Shapiro M, Herishanu Y, Katz BZ et al (2017) Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica 102(5):874\u2013882","journal-title":"Haematologica"},{"issue":"1","key":"17_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40164-023-00421-2","volume":"12","author":"J Tan","year":"2023","unstructured":"Tan J, Tan H, Li Y (2023) Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol 12(1):62","journal-title":"Exp Hematol Oncol"},{"key":"17_CR37","doi-asserted-by":"publisher","first-page":"1091782","DOI":"10.3389\/fonc.2022.1091782","volume":"12","author":"S Jin","year":"2022","unstructured":"Jin S, Zhang Y, Zhou F et al (2022) TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies. Front Oncol 12:1091782","journal-title":"Front Oncol"},{"issue":"2","key":"17_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/medsci7020014","volume":"7","author":"T Seto","year":"2019","unstructured":"Seto T, Sam D, Pan M (2019) Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer. Med Sci (Basel) 7(2):14. https:\/\/doi.org\/10.3390\/medsci7020014","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"17_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q (2023) Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med 20(3):181\u2013195","journal-title":"Cancer Biol Med"},{"issue":"5","key":"17_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3109\/10428194.2013.828354","volume":"55","author":"BZ Katz","year":"2014","unstructured":"Katz BZ, Herishanu Y (2014) Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma 55(5):999\u20131006","journal-title":"Leuk Lymphoma"},{"key":"17_CR41","doi-asserted-by":"publisher","first-page":"1165870","DOI":"10.3389\/fimmu.2023.1165870","volume":"14","author":"C Aparicio-P\u00e9rez","year":"2023","unstructured":"Aparicio-P\u00e9rez C, Carmona M, Benabdellah K, Herrera C (2023) Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol 14:1165870","journal-title":"Front Immunol"},{"issue":"2","key":"17_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","volume":"25","author":"EY Jen","year":"2019","unstructured":"Jen EY, Xu Q, Schetter A et al (2019) FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res 25(2):473\u2013477","journal-title":"Clin Cancer Res"},{"issue":"1","key":"17_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366","journal-title":"Lancet Oncol"},{"issue":"9","key":"17_CR44","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"16","key":"17_CR45","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795\u20131802","journal-title":"J Clin Oncol"},{"key":"17_CR46","doi-asserted-by":"crossref","unstructured":"Litzow MR, Sun Z, Mattison RJ et al (2024) Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med 391(4):320\u2013333.","DOI":"10.1056\/NEJMoa2312948"},{"issue":"14","key":"17_CR47","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"key":"17_CR48","doi-asserted-by":"publisher","first-page":"204062071989989","DOI":"10.1177\/2040620719899897","volume":"11","author":"T Jain","year":"2020","unstructured":"Jain T, Litzow MR (2020) Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol 11:2040620719899897","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"17_CR49","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K et al (2014) Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28(8):1596\u20131605","journal-title":"Leukemia"},{"issue":"1","key":"17_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/BS9.0000000000000140","volume":"5","author":"C Tian","year":"2023","unstructured":"Tian C, Chen Z (2023) Immune therapy: a new therapy for acute myeloid leukemia. Blood Sci 5(1):15\u201324","journal-title":"Blood Sci"},{"issue":"6","key":"17_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, Aldoss I, Foster MC et al (2021) Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 137(6):751\u2013762","journal-title":"Blood"},{"issue":"Supplement 1","key":"17_CR52","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.1182\/blood-2022-159524","volume":"140","author":"ES Winer","year":"2022","unstructured":"Winer ES, Maris M, Sharma MR et al (2022) A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific Dart\u00ae molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies. Blood 140(Supplement 1):11753\u201311754","journal-title":"Blood"},{"issue":"21","key":"17_CR53","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, Bashey A, Foran J et al (2023) Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv 7(21):6492\u20136505","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"17_CR54","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1182\/blood-2022-167468","volume":"140","author":"J Watts","year":"2022","unstructured":"Watts J, Maris M, Lin TL et al (2022) Updated results from a phase 1 study of APVO436, a novel bispecific anti-CD123 x anti-CD3 Adaptir\u2122 molecule, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood 140(Supplement 1):6204\u20136205","journal-title":"Blood"},{"issue":"16","key":"17_CR55","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.3390\/cancers13164113","volume":"13","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Lin TL, Mims AS et al (2021) A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancers 13(16):4113","journal-title":"Cancers"},{"issue":"3","key":"17_CR56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/cts.13467","volume":"16","author":"M Boyiadzis","year":"2023","unstructured":"Boyiadzis M, Desai P, Daskalakis N et al (2023) First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia. Clin Transl Sci 16(3):429\u2013435","journal-title":"Clin Transl Sci"},{"issue":"2","key":"17_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-017-0485-6","volume":"12","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Obinutuzumab: a review in rituximab-refractory or -relapsed follicular lymphoma. Target Oncol 12(2):255\u2013262","journal-title":"Target Oncol"},{"issue":"8","key":"17_CR58","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"5","key":"17_CR59","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH et al (2022) Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 9(5):e327\u2013e339","journal-title":"Lancet Haematol"},{"issue":"24","key":"17_CR60","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387(24):2220\u20132231","journal-title":"N Engl J Med"},{"issue":"12","key":"17_CR61","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 41(12):2238\u20132247","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"17_CR62","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2022-158404","volume":"140","author":"TM Kim","year":"2022","unstructured":"Kim TM, Taszner M, Cho S-G et al (2022) Odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the pivotal phase II study ELM-2. Blood 140(Supplement 1):2280\u20132282","journal-title":"Blood"},{"issue":"1","key":"17_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","volume":"11","author":"R Shao","year":"2023","unstructured":"Shao R, Li Z, Xin H et al (2023) Biomarkers as targets for CAR-T\/NK cell therapy in AML. Biomarker Res 11(1):65","journal-title":"Biomarker Res"},{"key":"17_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/jpm11050355","volume":"11","author":"R Salvaris","year":"2021","unstructured":"Salvaris R, Ong J, Gregory GP (2021) Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med 11:5","journal-title":"J Pers Med"},{"issue":"Supplement 1","key":"17_CR65","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1182\/blood-2022-157691","volume":"140","author":"NL Bartlett","year":"2022","unstructured":"Bartlett NL, Sehn LH, Matasar MJ et al (2022) Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: Updated results from a pivotal phase II study. Blood 140(Supplement 1):1467\u20131470","journal-title":"Blood"},{"issue":"10","key":"17_CR66","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R et al (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28(10):2145\u20132154","journal-title":"Nat Med"},{"issue":"10","key":"17_CR67","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A et al (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104\u20131111","journal-title":"J Clin Oncol"},{"issue":"11","key":"17_CR68","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G et al (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127(11):1410\u20131416","journal-title":"Blood"},{"issue":"1","key":"17_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06982-7","volume":"24","author":"M Topp","year":"2023","unstructured":"Topp M, Dlugosz-Danecka M, Skotnicki AB et al (2023) Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies. Trials 24(1):4","journal-title":"Trials"},{"issue":"Supplement","key":"17_CR70","doi-asserted-by":"publisher","first-page":"e60614fc","DOI":"10.1097\/01.HS9.0000967808.60614.fc","volume":"7","author":"R Jacobs","year":"2023","unstructured":"Jacobs R, Nair R, Cho SG et al (2023) S224: High complete response rate with TNB-486, a novel CD19xCD3 T-cell engager, in relapsed\/refractory follicular lymphoma: Interim results from an ongoing phase 1 study. Hemasphere 7(Supplement):e60614fc","journal-title":"Hemasphere"},{"issue":"16","key":"17_CR71","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C (2022) Teclistamab: first approval. Drugs 82(16):1613\u20131619","journal-title":"Drugs"},{"issue":"Supplement 16","key":"17_CR72","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, Donk NWCJvd et al (2024) Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 42(Supplement 16):7540\u20137540","journal-title":"J Clin Oncol"},{"issue":"7","key":"17_CR73","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R et al (2024) Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. Hemasphere 8(7):e136","journal-title":"Hemasphere"},{"key":"17_CR74","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter JR, Jagannath S et al (2024) Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 42:2702\u20132712","journal-title":"J Clin Oncol"},{"issue":"31","key":"17_CR75","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D'Souza","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C et al (2022) A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 40(31):3576\u20133586","journal-title":"J Clin Oncol"},{"key":"17_CR76","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"L Rasche","year":"2023","unstructured":"Rasche L, Schinke C, Touzeau C et al (2023) MM-492 long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM) Clin Lymphoma Myeloma. 2024; 24: S561-S562efractory multiple myeloma (RRMM). J Clin Oncol 41:8036\u20138036","journal-title":"J Clin Oncol"},{"issue":"Supplement 16","key":"17_CR77","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","volume":"40","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Krishnan AY, Berdeja JG et al (2022) Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1. J Clin Oncol 40(Supplement 16):8015\u20138015","journal-title":"J Clin Oncol"},{"issue":"1","key":"17_CR78","first-page":"20","volume":"32","author":"AMGA Laheij","year":"2023","unstructured":"Laheij AMGA, van de Donk NWCJ (2023) Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer 32(1):20","journal-title":"Support Care Cancer"},{"key":"17_CR79","doi-asserted-by":"publisher","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","volume":"12","author":"SF Cho","year":"2022","unstructured":"Cho SF, Yeh TJ, Anderson KC, Tai YT (2022) Bispecific antibodies in multiple myeloma treatment: a journey in progress. Front Oncol 12:1032775","journal-title":"Front Oncol"},{"issue":"11","key":"17_CR80","doi-asserted-by":"publisher","first-page":"e21776","DOI":"10.1016\/j.heliyon.2023.e21776","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang C, Wang J, Che S, Zhao H (2023) CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon 9(11):e21776","journal-title":"Heliyon"},{"issue":"1","key":"17_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T (2022) Exhaustion of CAR T cells: potential causes and solutions. J Transl Med 20(1):239","journal-title":"J Transl Med"},{"issue":"1","key":"17_CR82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ et al (2022) Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Res 10(1):24","journal-title":"Biomarker Res"},{"issue":"6","key":"17_CR83","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF et al (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"issue":"4","key":"17_CR84","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl 25(4):e123\u2013e127","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Supplement 1","key":"17_CR85","doi-asserted-by":"publisher","first-page":"10036","DOI":"10.1182\/blood-2022-169836","volume":"140","author":"S Sharma","year":"2022","unstructured":"Sharma S, Wang D, Lon H-K et al (2022) A systematic meta-analysis of cytokine release syndrome incidence in B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed and\/or refractory multiple myeloma. Blood 140(Supplement 1):10036\u201310038","journal-title":"Blood"},{"issue":"10301","key":"17_CR86","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301):665\u2013674","journal-title":"Lancet"},{"issue":"20","key":"17_CR87","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141(20):2430\u20132442","journal-title":"Blood"},{"issue":"7","key":"17_CR88","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1002\/hem3.132","volume":"8","author":"C Korst","year":"2024","unstructured":"Korst C, Groen K, Bosman PWC et al (2024) Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing. Hemasphere 8(7):e132","journal-title":"Hemasphere"},{"issue":"9","key":"17_CR89","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Chari A, Mateos MV (2024) Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol 11(9):e693\u2013e707","journal-title":"Lancet Haematol"},{"issue":"4","key":"17_CR90","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao Y, Hu Y, Wang F (2023) Trispecific antibodies for cancer immunotherapy. Immunol 169(4):389\u2013399","journal-title":"Immunol"},{"issue":"2","key":"17_CR91","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton AD, Nguyen DP, Gramespacher JA et al (2021) Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J Am Chem Soc 143(2):593\u2013598","journal-title":"J Am Chem Soc"},{"issue":"4","key":"17_CR92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 23(4):301\u2013319","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"17_CR93","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt ME et al (2025) Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 392(2):138\u2013149","journal-title":"N Engl J Med"},{"issue":"9","key":"17_CR94","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yu X, Wang X et al (2023) Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharmaceutica Sin B 13(9):3583\u20133597","journal-title":"Acta Pharmaceutica Sin B"},{"issue":"S4","key":"17_CR95","doi-asserted-by":"publisher","first-page":"S515","DOI":"10.1016\/j.htct.2024.09.865","volume":"46","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, van de Donk NWCJ, Rosinol L et al (2024) Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma: subgroup analysis by lines of therapies. Hematol Transfus Cell Ther 46(S4):S515","journal-title":"Hematol Transfus Cell Ther"},{"key":"17_CR96","doi-asserted-by":"publisher","unstructured":"G\u00f6kbuget Herv\u00e9 N, Massimiliano D, Albrecht B et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Abstract Blood 131(14):1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","DOI":"10.1182\/blood-2017-08-798322"},{"key":"17_CR97","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"Giovanni Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P et al (2021) Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. Eur J Cancer 146:107\u2013114. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.022","journal-title":"European Journal of Cancer"},{"key":"17_CR98","doi-asserted-by":"publisher","unstructured":"Short NJ, Bachireddy P, Huang X et al (2023) A phase II study of vibecotamab a CD3-CD123 bispecific T-cell engaging antibody for MRD-positive AML and MDS after hypomethylating agent failure. J Clin Oncol 41(16_suppl):TPS7076-TPS7076.https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS7076","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7076"},{"key":"17_CR99","doi-asserted-by":"publisher","unstructured":"Ravandi F, Walter RB, Subklewe M et al (2020) Updated results from phase I dose-escalation study of AMG 330 a bispecific T-cell engager molecule in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). J Clin Oncol 38(15_suppl):7508-7508. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508"},{"key":"17_CR100","doi-asserted-by":"publisher","unstructured":"Mei MG, Corazzelli G, Morschhauser F et al (2023) Safety and Preliminary Efficacy of Sabestomig (AZD7789) an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy.  Blood 142(Supplement 1):4433-4433. https:\/\/doi.org\/10.1182\/blood-2023-180926","DOI":"10.1182\/blood-2023-180926"},{"key":"17_CR101","doi-asserted-by":"publisher","unstructured":"Liu WP, Jiang B, Shuang YR et al (2023) Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood 142(Supplement 1):6158-6158. https:\/\/doi.org\/10.1182\/blood-2023-188071","DOI":"10.1182\/blood-2023-188071"},{"key":"17_CR102","doi-asserted-by":"publisher","unstructured":"Qi J, Sun M, Zhou K et al (2023) EX103 a Novel CD20xCD3 Bispecific Antibody Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed\/Refractory Patients with B-Cell Non-Hodgkin Lymphoma. Blood 142(Supplement 1):6230-6230. https:\/\/doi.org\/10.1182\/blood-2023-173486","DOI":"10.1182\/blood-2023-173486"},{"key":"17_CR103","doi-asserted-by":"publisher","unstructured":"Song Y, Li Z, Li L et al (2023) GB261 an Fc-Function Enabled and CD3 Affinity De-Tuned CD20\/CD3 Bispecific Antibody Demonstrated a Highly Advantageous Safety\/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma. Blood 142(Supplement 1):1719-1719. https:\/\/doi.org\/10.1182\/blood-2023-188444","DOI":"10.1182\/blood-2023-188444"},{"key":"17_CR104","doi-asserted-by":"publisher","unstructured":"Nair R, Jacobs R, Cho S-G et al (2023) High complete response rate with TNB-486 in relapsed\/refractory follicular lymphoma: Interim results from an ongoing phase 1 study. J Clin Oncol 142(16_suppl):7524-7524. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7524","DOI":"10.1200\/JCO.2023.41.16_suppl.7524"},{"key":"17_CR105","doi-asserted-by":"publisher","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 387(24):2220-2231. https:\/\/doi.org\/10.1056\/NEJMoa2206913","DOI":"10.1056\/NEJMoa2206913"},{"key":"17_CR106","doi-asserted-by":"publisher","unstructured":"Ayyappan S, Kim WS, Kim TM et al (2023) Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood 142(Supplement 1):436-436. https:\/\/doi.org\/10.1182\/blood-2023-179818","DOI":"10.1182\/blood-2023-179818"},{"key":"17_CR107","doi-asserted-by":"publisher","unstructured":"Suvannasankha A, Kapoor P, Pianko MJ et al (2023) Abstract CT013: Safety and efficacy from the phase 1\/2 first-in-human study of REGN5459 a BCMA\u00d7CD3 bispecific antibody with low CD3 affinity in patients with relapsed\/refractory multiple myeloma. Cancer Res 83(8_Supplement):CT013-CT013. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-CT013","DOI":"10.1158\/1538-7445.AM2023-CT013"},{"key":"17_CR108","doi-asserted-by":"publisher","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 387(24):2232-2244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","DOI":"10.1056\/NEJMoa2204591"},{"key":"17_CR109","doi-asserted-by":"publisher","unstructured":"Topp MS, Duell J, Zugmaier G et al (2020) Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol 38(8):775-783. https:\/\/doi.org\/10.1200\/JCO.19.02657","DOI":"10.1200\/JCO.19.02657"},{"key":"17_CR110","doi-asserted-by":"publisher","unstructured":"Lesokhin AM, Richter J, Trudel S et al (2022) Enduring Responses after 1-Year Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study. Blood 140(Supplement 1):4415-4417. https:\/\/doi.org\/10.1182\/blood-2022-157547","DOI":"10.1182\/blood-2022-157547"}],"container-title":["Methods in Molecular Biology","Bispecific Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5037-0_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:28:03Z","timestamp":1778452083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5037-0_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650363","9781071650370"],"references-count":110,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5037-0_17","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}